Finally, two additional clinical trials, supported by Graphite Bio, Inc [NCT04819841; GPH101-001; CEDAR] and Editas Medicine, [Inc NCT04853576; EM-SCD-301-001] explored the CRISPR-Cas9 system for ex vivo editing of CD34+cells from SCD patients [47]. Here, CD34 is linked to Schnyder corneal dystrophy.